Molecular Formula | C13H12N4O2S2
|
Molar Mass | 320.39 |
Density | 1.45±0.1 g/cm3(Predicted) |
Melting Point | 193 °C |
Boling Point | 522.4±60.0 °C(Predicted) |
Appearance | powder to crystal |
Color | White to Light yellow |
pKa | -0.14±0.30(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vitro study | SKLB1002 exhibits significantly reduced cytotoxicity to normal human cell L-02. By inhibiting VEGF-induced phosphorylation of VEGFR2 kinase and downstream protein kinases, including ERK,FAK, and Src ,SKLB1002 significantly inhibits HUVEC proliferation, migration, invasion, and lumen formation. |
In vivo study | In zebrafish embryos, SKLB1002 significantly blocked embryogenesis and tumor-induced angiogenesis with no or minimal effect on normal cell proliferation. In athymic mice xenografted with SW620 or HepG2, SKLB1002 (100 mg/kg/day, I. P.) caused significant tumor growth inhibition, inhibited tumor angiogenesis, and induced tumor cell apoptosis. In 4T1 and CT26 tumor models, SKLB1002 and local hyperthermia produce synergistic anti-tumor angiogenesis, anti-cancer, and apoptotic effects. |